Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial - PubMed (original) (raw)
Clinical Trial
Prophylaxis of serious cytomegalovirus infection in renal transplant candidates using live human cytomegalovirus vaccine. Interim results of a randomized controlled trial
K L Brayman et al. Arch Surg. 1988 Dec.
Abstract
We report the interim results of a randomized, double-blind, placebo-controlled, clinical trial of prophylactic, live, attenuated cytomegalovirus (CMV) vaccination (Towne strain of CMV) of renal transplant candidates (RTCs). One hundred seventy-two RTCs were treated and subsequently underwent transplantation and followed up for at least one year and up to five years after transplantation. Eighty-eight RTCs received vaccine, and 84 received placebo. Results were analyzed according to the prevaccination serologic status (anti-CMV antibody titer) of the recipient (R- or R+) and the donor (D- or D+). The overall incidence of CMV disease was highest in the R-D+ group and almost absent in the R-D- group. There was no difference in the incidence of CMV infection or disease between vaccinated and respective placebo control recipients in either the R-D+, R+D+, R+D-, or R-D- groups. In contrast, the severity of CMV disease was significantly decreased in R-D+ vaccinees vs R-D+ placebo-treated recipients. Moreover, in the R-D+ group, one- and five-year cadaver renal allograft actuarial survival rates were 73% and 62%, respectively, for CMV vaccinees vs 40% and 25%, respectively, for control placebo patients. We conclude that seronegative cadaver RTCs may benefit from vaccination with live, attenuated, Towne strain CMV vaccine before transplantation.
Similar articles
- Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.
Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. Plotkin SA, et al. Ann Intern Med. 1991 Apr 1;114(7):525-31. doi: 10.7326/0003-4819-114-7-525. Ann Intern Med. 1991. PMID: 1848053 Clinical Trial. - Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ, Malaise J, Moreno A, Crespo M, Fernández-Cruz L; Euro-SPK Study Group. Ricart MJ, et al. Nephrol Dial Transplant. 2005 May;20 Suppl 2:ii25-ii32, ii62. doi: 10.1093/ndt/gfh1079. Nephrol Dial Transplant. 2005. PMID: 15814546 Clinical Trial. - Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group. Witzke O, et al. Transplantation. 2012 Jan 15;93(1):61-8. doi: 10.1097/TP.0b013e318238dab3. Transplantation. 2012. PMID: 22094954 Clinical Trial. - Cytomegalovirus vaccines: current status.
Starr SE. Starr SE. Infect Agents Dis. 1992 Jun;1(3):146-8. Infect Agents Dis. 1992. PMID: 1365538 Review. - Prevention of cytomegalovirus infection in the pediatric renal transplant recipient.
Hibberd PL, Rubin RH. Hibberd PL, et al. Pediatr Nephrol. 1991 Jan;5(1):112-7. doi: 10.1007/BF00852867. Pediatr Nephrol. 1991. PMID: 1851031 Review.
Cited by
- Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.
Xia L, Su R, An Z, Fu TM, Luo W. Xia L, et al. Hum Vaccin Immunother. 2018 Feb 1;14(2):292-303. doi: 10.1080/21645515.2017.1391433. Epub 2017 Dec 1. Hum Vaccin Immunother. 2018. PMID: 29053403 Free PMC article. - A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection.
Crumpler MM, Choi KY, McVoy MA, Schleiss MR. Crumpler MM, et al. Vaccine. 2009 Jun 24;27(31):4209-18. doi: 10.1016/j.vaccine.2009.04.036. Epub 2009 May 3. Vaccine. 2009. PMID: 19389443 Free PMC article. - Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients.
Hughes D, Hafferty J, Fulton L, Friend P, Devaney A, Loke J, Welsh KI, Handa A, Klenerman P. Hughes D, et al. J Clin Virol. 2008 Feb;41(2):92-5. doi: 10.1016/j.jcv.2007.10.006. Epub 2007 Nov 26. J Clin Virol. 2008. PMID: 18032098 Free PMC article. - Infections in solid-organ transplant recipients.
Patel R, Paya CV. Patel R, et al. Clin Microbiol Rev. 1997 Jan;10(1):86-124. doi: 10.1128/CMR.10.1.86. Clin Microbiol Rev. 1997. PMID: 8993860 Free PMC article. Review. - Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis.
Ahmad T, Simmonds M, McIver AG, McGraw ME. Ahmad T, et al. Pediatr Nephrol. 1994 Aug;8(4):489-91. doi: 10.1007/BF00856544. Pediatr Nephrol. 1994. PMID: 7947045
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous